Universität zu Köln

Paffenholz, Pia, Votteler, Sinje, Nazari, Sassan, Nestler, Tim, Salem, Johannes, Grabbert, Markus, von Brandenstein, Melanie, Loosen, Sven H., Zey, Silke, Heidenreich, Axel, Herden, Jan and Denil, Johan (2019). Efficacy of the Oestrogen Antagonist Tamoxifen on Sperm Parameters in Patients with Idiopathic Oligoathenoteratozoospermia. Urol.Int., 103 (1). S. 108 - 116. BASEL: KARGER. ISSN 1423-0399

Full text not available from this repository.

Abstract

Background: The oestrogen antagonist tamoxifen has been suggested as an empiric treatment option for treating idiopathic oligoathenoteratozoospermia (iOAT). Objectives: To analyse the use of tamoxifen in iOAT. Method: Fifty-seven men receiving tamoxifen for iOAT were recruited from 2016 to 2017 in a retrospective, single-centre setting. Hormone and semen analysis was performed before and after 3 months of treatment. Results: After a 3-month treatment, serum levels of testosterone (3.4 ng/mL [2.7-4.8] vs. 5.3 [3.1-7.1]; p = 0.026), follicle stimulating hormone (FSH; 7.6 [5.9-11.5] vs. 15.9 mIU/mL [8.4-19.9]; p = 0.003) and luteinizing hormone (4.5 [3.3-6.6] vs. 7.6 mIU/mL [4.8-10.7]; p = 0.007) significantly increased. At a cut-off of >8.8 mIU/mL, serum levels of FSH were predictive for an improved sperm motility (OR 0.229 [95% CI 0.068-0.773]; p = 0.018) and serum levels of inhibin B were predictive for an improved total sperm count at a cut-off of <82 ng/L (OR 18.0 [95% CI 1.267-255.744]; p = 0.033). During an 11 month-follow-up, patients receiving tamoxifen showed a clinical pregnancy rate of 42%, leading to a live birth rate of 56% of all pregnant women. Twenty-three per cent of all patients reported non-serious adverse events. Conclusions: Tamoxifen is effective in improving the total sperm count as well as motility and can thus be safely used as empiric medical therapy in iOAT. (C) 2019 S. Karger AG, Basel

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Paffenholz, Pia UNSPECIFIED UNSPECIFIED UNSPECIFIED Votteler, Sinje UNSPECIFIED UNSPECIFIED UNSPECIFIED Nazari, Sassan UNSPECIFIED UNSPECIFIED UNSPECIFIED Nestler, Tim UNSPECIFIED UNSPECIFIED UNSPECIFIED Salem, Johannes UNSPECIFIED UNSPECIFIED UNSPECIFIED Grabbert, Markus UNSPECIFIED UNSPECIFIED UNSPECIFIED von Brandenstein, Melanie UNSPECIFIED UNSPECIFIED UNSPECIFIED Loosen, Sven H. UNSPECIFIED UNSPECIFIED UNSPECIFIED Zey, Silke UNSPECIFIED UNSPECIFIED UNSPECIFIED Heidenreich, Axel UNSPECIFIED UNSPECIFIED UNSPECIFIED Herden, Jan UNSPECIFIED UNSPECIFIED UNSPECIFIED Denil, Johan UNSPECIFIED UNSPECIFIED UNSPECIFIED
URN:	urn:nbn:de:hbz:38-160863
DOI:	10.1159/000500301
Journal or Publication Title:	Urol.Int.
Volume:	103
Number:	1
Page Range:	S. 108 - 116
Date:	2019
Publisher:	KARGER
Place of Publication:	BASEL
ISSN:	1423-0399
Language:	English
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language MALE-INFERTILITY; MEN; THERAPY; MODULATOR; CITRATE Multiple languages Urology & Nephrology Multiple languages
Refereed:	Yes
URI:	http://kups.ub.uni-koeln.de/id/eprint/16086